Poor survival linked to Puerto Rican women with triple-negative breast cancer subtype

Share this article:
Puerto Rican women with triple-negative breast cancer subtype have an increased risk of breast cancer death, according to a study presented at the 2010 AACR Conference on The Science of Cancer Health Disparities.

For the study, researchers analyzed data for 974 female patients with invasive breast cancer, among which 16.6% were triple negative, neither overexpressing HER2neu nor receptive to estrogen or progesterone.

The scientists reported that the risk of breast cancer death for Puerto Rican women who had the triple-negative breast cancer subtype was more than twice as high compared to women with other tumor subtypes. In addition, women who were age 50 years or younger at the time of diagnosis and had regional/distant disease were also more likely to die as a result of their breast cancer.

“Findings, which were consistent with results described in previous studies of U.S. populations, will be useful in the development of cancer control strategies in Puerto Rico and may have an impact on future studies of targeted therapies to improve breast cancer survival in other Hispanic populations,” concluded Ana Ortiz Martinez, MPH, PhD, associate professor and researcher at the University of Puerto Rico Cancer Center and the department of biostatistics and epidemiology, Graduate School of Public Health, University of Puerto Rico.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Improved tyrosine kinase inhibitor (TKI) selectively activates in tumor tissue, minimizing side ...

A new strategy developed by an interdisciplinary team of researchers aims to reduce the side effects connected to use of tyrosine kinase inhibitors (TKIs).

Prior cancer exclusion criteria may stymie potential of lung cancer clinical trials

A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.

Better adherence to guidelines for safe handling of antineoplastic drugs is needed

Recommended safe handling practices for workers who administer antineoplastic drugs in health care settings are not always followed, according to a new study.